After a cautious second half of 2025 marked by rising interest rates and conservative underwriting assumptions, January signaled a measured but noticeable return of private equity and strategic capital to the ASC sector. The U.S. ASC market, valued at approximately $45–47 billion in 2024, is projected to exceed $60 billion by 2029, with outpatient surgical volume expected to approach 110 million cases annually by 2033.

January deal activity reflected a sharper focus on operational resilience rather than headline growth alone. Buyers increasingly prioritized centers with diversified service lines, limited surgeon concentration, and predictable anesthesia cost structures. Common underwriting thresholds now include no single surgeon contributing more than 25–30% of total case volume, anesthesia expenses below 15% of net revenue, and payor concentration below 40% from any single contract.

Valuation dispersion widened materially. Well-structured ASCs with clean governance, stable management teams, and documented operational discipline continued to command EBITDA multiples in the 9–12× range. In contrast, centers with fragile staffing models, excessive surgeon dependence, or unresolved payor concentration issues were often capped at 5–6× EBITDA, regardless of raw volume or growth narratives.

January reinforced a clear market message: scale without durability no longer commands a premium. Resilience, diversification, and predictability now price higher than sheer case counts.